- Home
- ELVN vs MDXG Comparison
ELVN vs MDXG Comparison
Compare ELVN & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- MDXG
- Stock Information
- Founded
- ELVN 2016
- MDXG 2006
- Country
- ELVN United States
- MDXG United States
- Employees
- ELVN N/A
- MDXG N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- ELVN Health Care
- MDXG Health Care
- Exchange
- ELVN Nasdaq
- MDXG Nasdaq
- Market Cap
- ELVN 1.2B
- MDXG 1.1B
- IPO Year
- ELVN 2020
- MDXG N/A
- Fundamental
- Price
- ELVN $19.96
- MDXG $6.94
- Analyst Decision
- ELVN Strong Buy
- MDXG Buy
- Analyst Count
- ELVN 5
- MDXG 1
- Target Price
- ELVN $41.20
- MDXG $12.00
- AVG Volume (30 Days)
- ELVN 466.4K
- MDXG 430.1K
- Earning Date
- ELVN 11-12-2025
- MDXG 10-29-2025
- Dividend Yield
- ELVN N/A
- MDXG N/A
- EPS Growth
- ELVN N/A
- MDXG N/A
- EPS
- ELVN N/A
- MDXG 0.21
- Revenue
- ELVN N/A
- MDXG $363,774,000.00
- Revenue This Year
- ELVN N/A
- MDXG $12.68
- Revenue Next Year
- ELVN $25.00
- MDXG $8.18
- P/E Ratio
- ELVN N/A
- MDXG $33.06
- Revenue Growth
- ELVN N/A
- MDXG 6.85
- 52 Week Low
- ELVN $13.30
- MDXG $5.47
- 52 Week High
- ELVN $30.03
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- ELVN 49.34
- MDXG 46.16
- Support Level
- ELVN $18.80
- MDXG $6.81
- Resistance Level
- ELVN $21.30
- MDXG $7.14
- Average True Range (ATR)
- ELVN 1.00
- MDXG 0.19
- MACD
- ELVN -0.04
- MDXG -0.04
- Stochastic Oscillator
- ELVN 46.40
- MDXG 26.53
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.